A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Public ClinicalTrials.gov record NCT00000796. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine the demographic, behavioral, clinical, and geographic risk factors associated with the occurrence of multidrug-resistant pulmonary tuberculosis (MDRTB). To evaluate the clinical and microbiological responses and overall survival of MDRTB patients who are treated with levofloxacin-containing multiple-drug regimens chosen from a hierarchical list. Per 9/28/94 amendment, to assess whether persistent or recurrent positive sputum cultures of patients who show failure or relapse are due to the same strain or reinfection with a new strain. Among TB patients, there has been an increase in progressive disease due to the emergence of antimycobacterial drug-resistant strains of Mycobacterium tuberculosis. Failure to identify patients at high risk for MDRTB increases the hazard for both treatment failure and development of resistance to additional therapeutic agents. Efforts to improve survival in patients with MDRTB will depend on improved methods of assessing the risk of acquisition of MDRTB and identifying drug susceptibility patterns in a timely fashion.
Study identification
- NCT ID
- NCT00000796
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 525 participants
Conditions and interventions
Conditions
Interventions
- Cycloserine Drug
- Ethionamide Drug
- Capreomycin sulfate Drug
- Aminosalicylic acid Drug
- Streptomycin sulfate Drug
- Ethambutol hydrochloride Drug
- Amikacin sulfate Drug
- Isoniazid Drug
- Pyrazinamide Drug
- Pyridoxine hydrochloride Drug
- Levofloxacin Drug
- Rifampin Drug
- Clofazimine Drug
Drug
Eligibility (public fields only)
- Age range
- 13 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Sep 30, 1998
- Last update posted
- Nov 2, 2021
Ends 1998
United States locations
- U.S. sites
- 21
- U.S. states
- 3
- U.S. cities
- 5
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cook County Hosp | Chicago | Illinois | 60612 | — |
| Henry Ford Hosp | Detroit | Michigan | 48202 | — |
| Interfaith Med Ctr | Brooklyn | New York | 112032098 | — |
| SUNY / Health Sciences Ctr at Brooklyn | Brooklyn | New York | 112032098 | — |
| Beth Israel Med Ctr | New York | New York | 10003 | — |
| Clinical Directors Network of Region II | New York | New York | 10011 | — |
| Bellevue Hosp / New York Univ Med Ctr | New York | New York | 10016 | — |
| Saint Clare's Hosp and Health Ctr | New York | New York | 10019 | — |
| Cornell Univ Med Ctr | New York | New York | 10021 | — |
| Mount Sinai Med Ctr | New York | New York | 10029 | — |
| Columbia Presbyterian Med Ctr | New York | New York | 100323784 | — |
| Harlem AIDS Treatment Group / Harlem Hosp Ctr | New York | New York | 10037 | — |
| Bronx Lebanon Hosp Ctr | The Bronx | New York | 10456 | — |
| Bronx Municipal Hosp Ctr/Jacobi Med Ctr | The Bronx | New York | 10461 | — |
| Comprehensive Health Care Ctr / Bronx Municipal Hosp | The Bronx | New York | 10461 | — |
| Montefiore Drug Treatment Ctr / Bronx Municipal Hosp | The Bronx | New York | 10461 | — |
| Montefiore Family Health Ctr / Bronx Municipal Hosp | The Bronx | New York | 10461 | — |
| Samaritan Village Inc / Bronx Municipal Hosp | The Bronx | New York | 10461 | — |
| Jack Weiler Hosp / Bronx Municipal Hosp | The Bronx | New York | 10465 | — |
| Montefiore Med Ctr / Bronx Municipal Hosp | The Bronx | New York | 10467 | — |
| North Central Bronx Hosp / Bronx Municipal Hosp | The Bronx | New York | 10467 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00000796, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 2, 2021 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00000796 live on ClinicalTrials.gov.